Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Outcomes Following Brexucabtagene Autoleucel Administered as an FDA-Approved Therapy for Adults with Relapsed/Refractory B-ALL

June 27th 2023

Greg Roloff, MD, reviews data on the outcomes of patients with relapsed/refractory B-ALL who received treatment with brexucabtagene autoleucel.

MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia

June 26th 2023

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.

AZD4573 Elicits Responses in Relapsed/Refractory Peripheral T-cell Lymphoma

June 26th 2023

Single-agent treatment with the CDK9 inhibitor AZD4573 produced clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

June 23rd 2023

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma, including patients with disease progression after transplant or CAR T-cell therapy, and as a category 2A preferred regimen for patients with histologic transformation of indolent lymphoma to DLBCL with no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy.

New and Anticipated Advances Across Hematologic Malignancies Necessitate Improved Navigation of Current Options

June 23rd 2023

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma

June 22nd 2023

The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.

FDA Issues Complete Response Letter to NDA for ADX-2191 in Primary Vitreoretinal Lymphoma

June 22nd 2023

The FDA has issued a complete response letter to the new drug application seeking the approval of ADX-2191 for the treatment of patients with primary vitreoretinal lymphoma.

Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22nd 2023

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

June 22nd 2023

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Dr Frank on the Initial Efficacy and Safety of CAR22 in Relapsed/Refractory LBCL

June 21st 2023

Matthew Frank, MD, PhD, discusses preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

June 21st 2023

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

Favezelimab Plus Pembrolizumab Continues to Elicit Antitumor Activity in R/R Classical Hodgkin Lymphoma

June 21st 2023

The combination of favezelimab and pembrolizumab continued to demonstrate a manageable safety profile and antitumor activity in patients with relapsed/refractory classical Hodgkin lymphoma, irrespective of whether they received prior anti–PD-1 therapy.

FDA Approval Sought for Imetelstat for Transfusion-Dependent Anemia in Select MDS

June 21st 2023

A new drug application seeking the approval of imetelstat for use as a therapeutic option for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndrome who have not responded to, lost response to, or were not candidates for erythropoiesis-stimulating agents has been submitted to the FDA.

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

June 20th 2023

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin Lymphoma

June 19th 2023

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated Follicular Lymphoma, MZL

June 19th 2023

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma.